Back to top
more

Adherex Technologies (FENC)

(Delayed Data from NSDQ)

$11.71 USD

11.71
198,353

+0.31 (2.72%)

Updated Aug 25, 2026 04:00 PM ET

After-Market: $11.69 -0.02 (-0.17%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.80%
2Buy18.13%
3Hold10.19%
4Sell5.73%
5Strong Sell3.17%
S&P50011.53%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value B Growth A Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 35% (159 out of 246)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

Cue Biopharma, Inc. (CUE) Reports Q2 Loss, Tops Revenue Estimates

by Zacks Equity Research

Cue Biopharma (CUE) delivered earnings and revenue surprises of +30.77% and +47.70%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Roivant Sciences Ltd. (ROIV) Reports Q1 Loss, Misses Revenue Estimates

by Zacks Equity Research

Montes Archimedes Acquisition (ROIV) delivered earnings and revenue surprises of +21.74% and -71.42%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Concentra Group (CON) Matches Q2 Earnings Estimates

by Zacks Equity Research

Concentra (CON) delivered earnings and revenue surprises of 0.00% and +2.61%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Are Medical Stocks Lagging Editas Medicine (EDIT) This Year?

by Zacks Equity Research

Here is how Editas Medicine (EDIT) and Adherex Technologies Inc. (FENC) have performed compared to their sector so far this year.

Zacks Equity Research

Recent Price Trend in Adherex Technologies (FENC) is Your Friend, Here's Why

by Zacks Equity Research

Adherex Technologies (FENC) could be a great choice for investors looking to make a profit from fundamentally strong stocks that are currently on the move. It is one of the several stocks that made it through our "Recent Price Strength" screen.

Zacks Equity Research

The Joint Misses Q1 Earnings Estimates on Rising Expenses

by Zacks Equity Research

JYNT expects to open 30-40 franchised clinics in 2025, down from 57 last year.

Zacks Equity Research

Acadia Healthcare Q1 Earnings Top Estimates on Rising Admissions

by Zacks Equity Research

ACHC continues to witness growth in patient days. It authorizes a share repurchase program of almost $300 million.

Zacks Equity Research

Adherex Technologies Inc. (FENC) Reports Q1 Loss, Tops Revenue Estimates

by Zacks Equity Research

Adherex Technologies (FENC) delivered earnings and revenue surprises of 66.67% and 9.32%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Cue Biopharma, Inc. (CUE) Reports Q1 Loss, Misses Revenue Estimates

by Zacks Equity Research

Cue Biopharma (CUE) delivered earnings and revenue surprises of -21.43% and 78.95%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Acadia Pharmaceuticals (ACAD) Tops Q1 Earnings and Revenue Estimates (Revised)

by Zacks Equity Research

Acadia (ACAD) delivered earnings and revenue surprises of 10% and 1.23%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?